Table 1 Characteristics of each study included in the final analysis
Serial no | Authors | Year | Country | Gender wise distribution (M/F) | SOC | Sample size | Genotyping | NOS score | |
|---|---|---|---|---|---|---|---|---|---|
Cases (N) | Controls (N) | ||||||||
1 | Behiry | 2019 | Egypt | 44% = M 56% = F | PB | 150 | 90 | PCR-Sequencing | 8 |
2 | Peng | 2010 | China | NA | PB | 135 | 114 | PCR-Sequencing | 7 |
3 | Cao | 2015 | China | 29 = M 41 = F | HB | 70 | 136 | PCR-Sequencing | 7 |
4 | Ketharnathan | 2015 | India | 26 = M 24 = F | PB | 50 | 50 | PCR-Sequencing/RT-PCR | 8 |
5 | Pang | 2012 | China | 110 = M 103 = F | HB | 213 | 194 | PCR-Sequencing | 8 |
6 | Dinesh | 2010 | India | NA | PB | 150 | 70 | PCR-Sequencing | 7 |
7 | Ouyang | 2011 | China | NA | PB | 125 | 105 | PCR-Sequencing | 7 |
8 | Wang et al. | 2019 | China | 157 = M 282 = F | PB | 439 | 567 | Multiplex PCR, qPCR, Sequencing | 8 |
9 | Liu [1] | 2009 | China | NA | PB | 160 | 200 | PCR-Sequencing | 7 |
10 | Liu [2] | 2009 | China | NA | PB | 180 | 200 | PCR-Sequencing | 7 |
11 | Han | 2011 | China | NA | 81 | 52 | 7 | ||
12 | Xie | 2013 | China | 71 = M 65 = F | PB | 136 | 200 | PCR-Sequencing | |
13 | Xiong | 2013 | China | 166 = M 58 = F | PB | 224 | 121 | PCR, DHPLC-Sequencing | 7 |
14 | Yin | 2018 | China | 59 = M 39 = F | PB | 98 | 200 | PCR-direct sequence analysis | 8 |
15 | Zhang | 2009 | China | 132 = M 98 = F | PB | 230 | 200 | PCR, denaturing high-performance liquid chromatography, and sequencing | 8 |
16 | Zhao | 2020 | China | NA | HB | 620 | 620 | PCR, MassARRAY system | 8 |
17 | Shi | 2005 | China | NA | NA | 110 | 110 | –– | 8 |